摘要
目的探讨吉西他滨(GEM)化疗结合槐耳综合治疗进展期无法切除胰腺癌的临床疗效。方法对85例无法切除胰腺癌患者进行前瞻性随机对比研究,其中,42例GEM化疗患者归为A组,43例GEM化疗+槐耳治疗患者归为B组。并取同期未行以上治疗的23例患者作为空白对照,归为C组。分析比较各组临床疗效。结果处理后,A、B组血液系统反应发生率差异有统计学意义(P<0.05),而B组IgA、IgG、IgM值,NK细胞、CD3+T细胞亚群百分比及CD4+/CD8+比值均显著高于A组(P<0.05)。A、B组的临床受益率于第3个月时差异有统计学意义(P<0.05),但A、B组间的差异无统计学意义(P>0.05);第6个月时B组显著高于A组(P<0.05)。A、B组的客观有效率差异无统计学意义(P>0.05)。3组的1年累积生存率分别为23.35%、25.76%和10.14%,A、B组显著高于C组(P<0.05),但前2组间的差异无统计学意义(P>0.05)。结论GEM化疗联合槐耳治疗,在改善无法切除胰腺癌客观缓解率及生存时间方面无统计学证据,但对化疗血液系统反应、免疫功能及生存质量等方面有显著疗效。
Objective To study the clinical effectiveness of gemcitabine and trametes robiniphila murr in the treatment of unresectable pancreatic cancer. Methods In this prospective randomized controlled study, 85 cases of unresectable pancreatic cancer were selected during July 2004 to September 2006, included 42 cases receiving gemcitabine chemotherapy （group A） and 43 cases receiving gemcitabine ＋ trametes robiniphila murr （group B）, and 23 cases not subject to above treatments served as control group. The clinical effectiveness among groups were compared. Results The incidence of blood sideeffect in groups A and B was 76.19 % and 48.84 % after treatment, and the difference was significant （ P 〈0.05）. After chemotherapy ,the levels of IgA, IgG and IgM,the percentage of NK cells and CD3＋ , rate of CD4 ＋/CD8 ＋ in group B were significantly higher than in group A （ P 〈 0.05 ）. The rates of clinical benefit response were 38.10 %, 37.21% and 13.04 % respectively on the 3rd month in groups A, B and C, and the difference between groups A, B and C （ P 〈 0.05）, and those were 20.00 %, 44.12% and 0.00% on the 6th month,higher in groups A and B than in group C or higher in group B than in group A （ P 〈0.05）.The rates of objective tumor response in groups A,B and C were 26.19%, 25.58% and 0.00% respectively on the 3rd month,20.00% ,17.65% and 0.00% on the 6th month. The median survival in groupd A, B and C was 10.13,9.96 and 7.73 months respectively, and the oneyear survival rate was 23.35 % ,25.76 % and 10.14 % respectively, with the difference being significant between groups A, B and C. Conclusion Gemcitabine chemotherapy combined with trametes robiniphila murr had no statistical evidence in the treatment of unresectable pancreatic cancer, but it alleviated the side- effect of chemotherapy, and improved quality of llfe and immune function.
出处
《临床外科杂志》
2007年第4期240-242,共3页
Journal of Clinical Surgery
基金
湖北省科技攻关项目(NO:2006AA301C30)
关键词
胰腺肿瘤
吉西他滨
槐耳
治疗
预后
pancreatic cancer
gemcitabine
trametes robiniphila murr
treatment
prognosis
